<code id='092758CFD6'></code><style id='092758CFD6'></style>
    • <acronym id='092758CFD6'></acronym>
      <center id='092758CFD6'><center id='092758CFD6'><tfoot id='092758CFD6'></tfoot></center><abbr id='092758CFD6'><dir id='092758CFD6'><tfoot id='092758CFD6'></tfoot><noframes id='092758CFD6'>

    • <optgroup id='092758CFD6'><strike id='092758CFD6'><sup id='092758CFD6'></sup></strike><code id='092758CFD6'></code></optgroup>
        1. <b id='092758CFD6'><label id='092758CFD6'><select id='092758CFD6'><dt id='092758CFD6'><span id='092758CFD6'></span></dt></select></label></b><u id='092758CFD6'></u>
          <i id='092758CFD6'><strike id='092758CFD6'><tt id='092758CFD6'><pre id='092758CFD6'></pre></tt></strike></i>

          focus

          focus

          author:leisure time    Page View:5193
          Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference
          JUSTIN TALLIS/AFP via Getty Images

          LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

          At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

          advertisement

          In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more
          Biotech incubator Curie.Bio graduates its first startup
          Biotech incubator Curie.Bio graduates its first startup

          ChristophLengauer,co-founderandCSOofCurie.BioVanessaLeroyforSTATCurie.Bio,thenewbiotechinvestmentfir

          read more
          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more

          Ambulance rides for just $100? Advisers want major billing fixes

          AdobeApanelofgovernmentadvisersfinallyhasendorsedideasforCongresstosolvetheparticularlythornyproblem